In female mice fed a HFD and HCD, the combination of purified n–3 fatty acids (n–3) and SC-560 (SC), a cyclooxygenase-1-specific inhibitor, induced both Pxr and Fxr and reduced Fgfr4 expression, leading to upregulation of genes involved in bile synthesis and/or detoxification, and ameliorating nonalcoholic fatty liver disease. This evidence concerns the gene NR1I2 and metabolic dysfunction-associated steatotic liver disease.